1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.

INTI
Inhibitor Therapeutics, Inc.US flagOther OTC
0.08
USD
+0.00
- -
13.37MMarket Cap
Inhibitor Therapeutics, Inc.
INTI
(Other OTC)

Recent

price

0.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.1
-0.02
0.01
-0.1
-0.04
-0.02
-0.02
-0.01
-0.01
-0.01
- -
- -
0.03
-0.02
-0.02
-0.02
-0.02
Basic EPS, GAAP
-0.02
0.01
-0.03
-0.07
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
- -
- -
0.03
-0.02
-0.02
-0.02
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.67
-2.2
-1.94
-1.57
-0.34
-0.16
-0.15
-0.13
-0.14
-0.15
-0.15
-0.15
-0.12
-0.28
-0.3
-0.32
-0.33
Book Value per Share
0.04
-0.03
-0.01
-0.04
- -
- -
0.02
- -
-0.01
-0.02
-0.02
-0.02
0.02
0.03
0.01
-0.01
-0.01
Tangible Book Value per Share
10
12
14
18
96
233
289
367
370
370
372
376
366
172
172
173
173
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
- -
- -
-2
-4
-4
-7
-5
-5
-3
-1
- -
12
-3
-3
-3
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.45
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
1
1
- -
-1
- -
- -
7
- -
- -
- -
- -
-1
11
8
5
2
1
Working Capital
4
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
-1
- -
- -
7
- -
- -
-3
-3
-4
8
5
2
-1
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-24.63
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
-0.71
- -
- -
- -
- -
- -
- -
- -
- -
- -
-24.56
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
173
173
173
Market Capitalization
9
8
19

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
3
2
1
Cash, Cash Equivalents & STI
3
2
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
1
- -
Payables & Accruals
- -
1
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-709.65%
-117.04%
-165.08%
Free Cash Flow
-562.85%
-1,120.55%
-0.05%
Net Income, GAAP
-440.34%
-868.3%
-1.16%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.02
2025
- -
- -
- -
- -
-0.02
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Xeris Biopharma Holdings, Inc. (XERS)
Suzhou Ribo Life Science Co (6938.HK)
Probi AB (publ) (PBBIF)
BioRestorative Therapies, Inc. (BRTX)
Catabasis Pharmaceuticals, Inc. (CATB)
Antengene Corporation Limited (6996.HK)
Business
Inhibitor Therapeutics, Inc. (INTI) is a clinical-stage biopharmaceutical company that develops and commercializes repurposed, patent-protected therapeutics derived from approved active pharmaceutical ingredients for oncology and non-cancerous proliferation disorders; its lead candidate, SUBA-Itraconazole, is a patented oral formulation of itraconazole targeted at basal cell carcinoma nevus syndrome, prostate cancer, and lung cancer, supported by owned intellectual property including U.S. patents on hedgehog pathway inhibitors for these indications. The company operates primarily in the United States, serving patients with certain cancers through innovative therapies leveraging FDA-approved antifungals like itraconazole in novel oncology applications. Founded in 1992 and headquartered in Tampa, Florida, Inhibitor Therapeutics maintains a lean operation with approximately six employees and trades on the OTCQB market. In recent developments, the company engages Avior Bio, Inc. to create a novel itraconazole formulation with results expected in the first half of 2025, furthering its pre-IND clinical plans; it provided a clinical development update in August 2024 and continues to explore licensing or acquiring additional pre-clinical and clinical-stage therapeutics.

Company News

APIChatGPT

  • globenewswire.com

    Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome

  • globenewswire.com

    Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024

  • globenewswire.com

    Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight

  • globenewswire.com

    Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan

  • zacks.com

    3 Intriguing Stocks to Watch as Earnings Approach

  • prnewswire.com

    Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board